HSP Gp96 vaccine - Cure and Sure Biotech

Drug Profile

HSP Gp96 vaccine - Cure and Sure Biotech

Alternative Names: Autologous Gp96 vaccine - Cure & Sure Biotech; Autologous heat shock protein Gp96 vaccine - Cure & Sure Biotech; Autologous tumour derived HSP Gp96 vaccine - Cure & Sure Biotech; HSP Gp96 vaccine - Cure & Sure Biotech

Latest Information Update: 15 Jan 2015

Price : $50

At a glance

  • Originator Cure&Sure Biotech
  • Developer Chinese Academy of Medical Sciences; Chinese PLA General Hospital; Cure&Sure Biotech
  • Class Cancer vaccines; Protein-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Gastric cancer; Liver cancer; Pancreatic cancer
  • Phase I Glioblastoma

Most Recent Events

  • 01 Nov 2014 Phase-I/II clinical trials in Gastric cancer in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top